Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29901355 | 0.81 | HRH3 (0.46) | POLBSLC6A2HRH3HCAR3P2RX7 | |
| SCHEMBL14344891 | 0.79 | SLC6A2 (0.43) | SLC6A2HRH3ALDH1A1P2RX7HSP90AA1 | |
| SCHEMBL30775420 | 0.79 | SLC6A2 (0.43) | SLC6A2HRH3ALDH1A1P2RX7HSP90AA1 | |
| SCHEMBL2104942 | 0.77 | SLC6A2 (0.39) | POLBSLC6A2HRH3HSD17B10MAPK1 | |
| SCHEMBL31490354 | 0.76 | POLB (0.58) | POLBSLC6A2HSD17B10MAPTMAPK1 | |
| SCHEMBL440638 | 0.76 | POLB (0.58) | POLBSLC6A2HSD17B10MAPTMAPK1 | |
| SCHEMBL22931659 | 0.73 | HSP90AA1 (0.42) | SLC6A2HRH3EGFRMAPTP2RX7 | |
| SCHEMBL1321225 | 0.73 | — | — | |
| SCHEMBL30775432 | 0.73 | — | — | |
| Alcohol SCHEMBL7553089 | 0.73 | POLB (0.54) | POLBSLC6A2HSD17B10MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-12-22 | — | — | US | disclosed |
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238424-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2019-12-19 | — | — | WO | disclosed |
| US-7001910-B1 | Thiazolidinedione derivatives as antidiabetic agents | VITA-INVEST S.A. (ES) | 2006-02-21 | — | — | US | disclosed |
| EP-1231211-B1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTIDIABETIC AGENTS | VITA INVEST SA (ES) | 2003-05-28 | — | — | EP | disclosed |
| EP-1231211-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTIDIABETIC AGENTS | VITA-INVEST, S.A. (ES) | 2002-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1A, TNF, IL6 | POLB 1280/4885SLC6A2 4161/4885HRH3 1102/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | POLB 1397/4885SLC6A2 3874/4885HRH3 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.